A recessive ryanodine receptor 1 mutation in a CCD patient increases channel activity by Ghassemi, Farshid et al.
A recessive ryanodine receptor 1 mutation in a CCD patient
increases channel activity
Farshid Ghassemi1, Mirko Vukcevic2, Le Xu1, Haiyan Zhou3, Gerhard Meissner1, Francesco
Muntoni3, Heinz Jungbluth4, Francesco Zorzato5, and Susan Treves2,#
1 Departments of Biochemistry and Biophysics and Molecular and Cellular Physiology, University of North
Carolina, Chapel Hill, NC 27599-7260, USA 2 Departments of Anaesthesia and Biomedical Research, Basel
University Hospital, 4031 Basel, Switzerland 3 The Dubowitz Neuromuscular Centre, UCL Institute of Child
Health, London WC1N 1EH, U.K 4 Department of Paediatric Neurology, Neuromuscular Service, Evelina
Children’s Hospital, St. Thomas’ Hospital, Lambeth Palace Road, London SE1 7EH, UK 5 Dipartimento di
Medicina Sperimentale e Diagnostica, Universita’ di Ferrara, 44100 Ferrara, Italy
SUMMARY
Ryanodine receptors plays a crucial role in skeletal muscle excitation-contraction coupling by
releasing calcium ions required for muscle contraction from the sarcoplasmic reticulum. At least
three phenotypes associated with more than 100 RYR1 mutations have been identified; in order to
elucidate possible pathophysiological mechanisms of RYR1 mutations linked to neuromuscular
disorders, it is essential to define the mutation class by studying the functional properties of channels
harboring clinically relevant amino acid substitutions. In the present report we investigated the
functional effects of the c.7304G>T RYR1 substitution (p.Arg2435Leu) found in a patient affected
by central core disease. Both parents were heterozygous for the substitution while the proband was
homozygous. We characterized Ca2+ homeostasis in myoD transduced myotubes from controls, the
heterozygous parents and the homozygous proband expressing the endogenous mutation. We also
expressed the recombinant mutant channels in heterologous cells and characterized their [3H]
ryanodine binding and single channel properties. Our results show that the p.Arg2435Leu substitution
affects neither the resting [Ca2+], nor the sensitivity of the ryanodine receptor to pharmacological
activators, but rather reduces the release of Ca2+ from intracellular stores induced by pharmacological
activators as well as by KCl via the voltage sensing dihydropyridine receptor.
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INTRODUCTION
The ryanodine receptor (RyR) ion channels are large protein complexes composed of four RyR
560 kDa peptides and various associated proteins with a total molecular weight of greater than
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2,500 kDa. They play a crucial role in skeletal muscle excitation-contraction coupling by
releasing calcium ions required for muscle contraction from the sarcoplasmic reticulum [1–
3]. Mutations in the skeletal muscle isoform of the ryanodine receptor, which is encoded by a
gene located on human chromosome 19, are associated with at least three neuromuscular
disorders and may be linked to certain forms of heat stroke [4–7]. Four phenotypes associated
with more than 100 RYR1 mutations have been identified to date; most commonly, dominant
mutations have been found to associate with typical central core disease (CCD; OMIM #
117000) and the malignant hyperthermia susceptibility trait (MHS) (MH; OMIM #145600)
[4,5], whereas few recessive mutations have been identified in patients affected by clinically
distinct forms of multi-minicore disease (MmD) (MmD; OMIM # 602771) and forms of CCD
with unusual or more severe presentations [8–11]. In most cases, dominant RYR1 mutations
linked to CCD localize to the COOH-terminal domain of the channel, containing the
transmembrane and pore-forming domains of the RyR1 channel, whereas MHS-linked
mutations were initially mapped to hot spot areas within the NH2 and central RyR domains;
however, more recently identified MHS-linked mutations seem to be distributed throughout
the entire RYR1 coding region.
It appears that RYR1 mutations result in 4 different channel defects [6]: (i) one class of
mutations (mostly associated with MHS phenotype) cause Ca2+ channels to become
hypersensitive to membrane depolarisation and pharmacological activation; (ii) a second class
of mutations causes the RyR1 channels to become leaky (iii) a third class of mutations renders
the Ca2+ channel unable to conduct Ca2+ and/or uncouples RyR1 from the voltage sensor
[12], (mutation class 2 and 3 are mostly associated to CCD); (iv) the forth class of mutations
(found in hemyzygous MmD patients) results in protein Ca2+ channel instability which
ultimately leads to a decrease of the expression level within muscle [10,13]. In order to elucidate
possible pathophysiological mechanisms of neuromuscular disorders linked to RYR1 mutation,
it is essential to define the mutation class by studying the functional properties of channels
harbouring clinically relevant amino acid substitutions.
One of the first mutations identified in RYR1 associated with the CCD phenotype, was the
heterozygous A>G7302 substitution, leading to the p.Arg2434His mutation [14]. This
substitution was also identified at the heterozygous level in some patients who were classified
as MHS by the in vitro contracture test [15–17]. Functional analysis indeed confirmed that
when expressed as a recombinant channel in heterologous HEK293 cells, the presence of this
mutation led to a shift in sensitivity to both caffeine and halothane [18]. A similar
p.Arg2435Leu substitution was also identified at the heterozygous state in some MHS and
CCD families [15,16,19].
Recently, we characterized a large cohort of patients with clinical, histological and muscle
imaging features suggestive of RYR1 involvement and identified nine novel mutations,
including the homozygous substitution c.7304G>T leading to a p.Arg2435Leu mutation in a
patient affected by CCD [20]. Because in some patients affected by core myopathies,
monoallelic expression of the mutation has been found in muscles [10,20,21], we undertook a
more detailed investigation of the patient and her family members. Both parents were
heterozygous for the p.Arg2435Leu substitution while the affected proband was homozygous,
confirming the classical Mendelian inheritance of this mutation. Since both parents were
unaffected, we reasoned that the genotype-phenotype correlation might be linked to the
presence of the mutation at the homozygous state. In the present study we (i) characterized
Ca2+ homeostasis in MyoD transduced myotubes from controls, heterozygous parents and the
homozygous proband expressing the endogenous mutation and (ii) expressed the recombinant
mutant channel in heterologous cells and characterized its [3H]ryanodine binding
characteristics and single channel properties. Our results show that the presence of the
p.Arg2435Leu substitution either at the homozygous or heterozygous state, affects neither
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resting [Ca2+], nor the sensitivity of the ryanodine receptor to pharmacological activators, but
rather increases ryanodine receptor ion channel activity, leading to reduced Ca2+ release after
activation by pharmacological agents.
METHODS
Patient phenotype and family history
The patient is currently a 15 years old girl who presented, following an unremarkable perinatal
history and normal early normal development, at the age of 3–4 years with toe walking and a
hyperlordotic posture. At age 6 years she was operated for contractures of the Achilles tendons
and the muscle biopsy performed at the time, was consistent with central core disease.
Subsequently, in addition to her hyperlordosis, she developed a moderate scoliosis and bilateral
scapular winging; on examination she had a mild Gowers’ sign but was able to jump. Her CK
was 700 IU/l. There was no known consanguinity although both parents originate from the
same town in Italy. There was no history of MH in the parents (the mother has undergone
anaesthesia on two separate occasions) or in other family members; no MH test has ever been
done in her family but both parents are aware that they both have moderately increased CK
(300 IU/l). Genetic investigation [20] showed that the parents carried the heterozygous
substitution c.7304G>T in exon 45 and that the patient was homozygous for the substitution.
Screening of the entire RYR1 cDNA did not reveal the presence of any other nucleotide
changes.
MyoD transduced fibroblasts
It was not possible to obtain myotubes from the muscle biopsies but primary skin fibroblast
cultures were established from the proband and unaffected parents. Functional studies were
performed on fibroblasts transduced with myoD-encoding adenovirus in order to achieve
myogenic conversion, as previously described [13].
Intracellular calcium measurements
Changes in the intracellular Ca2+ concentration, [Ca2+]i, of myotubes were monitored with the
fluorescent Ca2+ indicator fura-2 at the single cell level by digital imaging microscopy as
previously described [13,22]. Individual cells were stimulated with a 12-way 100 mm diameter
quartz micromanifold computer controlled microperfuser (ALA Scientific). On-line (340 nm,
380 nm and ratio) measurements were recorded using a fluorescent Axiovert S100 TV inverted
microscope (Carl Zeiss GmbH, Jena, Germany) equipped with a 20x water-immersion FLUAR
objective (0.17 NA), filters (BP 340/380, FT 425, BP 500/530). Cells were analyzed using an
Openlab imaging system and the average pixel value for each cell was measured at excitation
wavelengths of 340 and 380 nm.
Construction of mutant cDNAs and expression of wild-type and mutant RyR1 proteins in
HEK293 cells
Base changes of rabbit RyR1 cDNA were performed by Pfu-turbo polymerase-based chain
reaction using mutagenic oligonucleotides and the QuikChange site-directed mutagenesis kit
(Stratagene, La Jolla, CA) as described previously [23]. Briefly, a fragment of RyR1 cDNA
(XhoI-BbrPI (6598–7692)), subcloned into cloning vector, served as a template for PCR. The
mutant fragment amplified by PCR, was confirmed by DNA sequencing and cloned back into
the original position by standard cloning techniques. Finally, expression plasmids for full-
length RyR1 with the mutation were constructed by ligating three RyR1 fragments (ClaI/
XhoI (polylinker-6598), XhoI/EcoRI (6598–11767), EcoRI/XbaI (11767-polylinker)) and
pCMV5 (ClaI/XbaI) expression vector. Nucleotide numbering is as described previously
[24].
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Wild-type RyR1 and mutant cDNAs were transiently expressed in HEK293 cells transfected
with FuGENE 6 according to the manufacturer’s instructions. Cells were maintained at 37°C
and 5% CO2 in high glucose Dulbecco’s modified eagle medium containing 10% fetal bovine
serum and plated the day before transfection. For each 10 cm tissue culture dish, 3.5 μg of
cDNA was used. Cells were harvested 48 h after transfection. Crude membrane fractions and
proteoliposomes containing the purified RyR1s were prepared in presence of protease
inhibitors as described [23].
[3H]PN200-110 and [3H]Ryanodine Binding
[3H]PN200-110binding experiments were carried out on the 10K supernatant of MyoD
transduced cells from controls or the homozygous p.Arg2435Leu mutation bearing patient as
previously described [25].
[3H]Ryanodine binding experiments were performed with crude membrane fractions prepared
from HEK 293 cells as previously described [23]. Unless otherwise indicated, membranes were
incubated with 3 nM [3H]ryanodine in 20 mM imidazole, pH 7.0, 0.15 M sucrose, 250 mM
KCl, 5 mM Mg2+, 5mM AMPPCP (a non-hydrolyzable ATP analogue), 5 mM reduced
glutathione, protease inhibitors, 1 mM EGTA and [Ca2+] to yield the indicated concentrations
of free Ca2+. Free [Ca2+] were adjusted with the use of a Ca2+ selective electrode. Nonspecific
binding was determined using a 1000–2000 fold excess of unlabeled ryanodine. After 20 h,
samples were diluted with 8 volumes of ice-cold water and placed on Whatman GF/B filters
preincubated with 2% polyethyleneimine in water. Filters were washed with three 5 ml ice-
cold 100 mM KCl, 1 mM KPipes, pH 7.0 solution. The radioactivity remaining with the filters
was determined by liquid scintillation counting to obtain bound [3H]ryanodine.
Bmax values of [3H]ryanodine binding were determined by incubating membranes for 4 h at
24°C with a saturating concentration of [3H]ryanodine (30 nM) in 20 mM imidazole, pH 7.0,
0.6 M KCl, 0.15 M sucrose, 1 mM glutathione (oxidized), protease inhibitors, and 200 μM
Ca2+. Specific binding was determined as described above.
Single channel recordings
Single channel measurements were performed using planar lipid bilayers containing a 5:3:2
mixture of bovine brain phosphatidylethanolamine, phosphatidylserine, and
phosphatidylcholine (25 mg of total phospholipid/ml n-decane as previously described [12].
Proteoliposomes containing the purified recombinant RyR1s were added to the cis (SR
cytosolic side) chamber of a bilayer apparatus and fused in the presence of an osmotic gradient
(250 mM cis KCl/20 mM trans KCl in 20 mM KHepes, pH 7.4, 0.23 mM EGTA and 0.21 mM
Ca2+). After the appearance of channel activity, trans (SR lumenal side) KCl concentration
was increased to 250 mM to prevent further fusion of proteoliposomes. To determine K+ and
Ca2+ conductances and permeability ratios, single channel activities were recorded in
symmetrical 250 mM KCl solution before and after addition of 10 mM Ca2+ to the trans side,
and analyzed as described [12].
Statistical analysis
Statistical analysis was performed using the Student’s t test for paired samples or using
ANOVA when more than two groups were compared. Origin computer program (Microcal
Software, Inc., Northampton, MA, USA) was used for statistical analysis and dose response
curve generation.
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In order to assess the functional effect of the p.Arg2435Leu mutation, we used myotubes
derived from MyoD transduced fibroblasts obtained from controls, the heterozygous parents
and the homozygous patient. We have previously shown that such myotubes express a
functional RyR1 ion channel and represent a valid model to assess the effects of RyR1
mutations on stored Ca2+ release [13]. We determined the resting [Ca2+], the dose dependent-
sensitivity of the myotubes to caffeine and 4-chloro-m-cresol and the peak Ca2+ release from
fura-2 laded myotubes, since we have previously demonstrated that most pathogenic RYR1
mutations can alter any of these parameters [13,22]. Figures 1A and B show that the presence
of the p.Arg2435Leu substitution at the heterozygous or homozygous state did not increase the
sensitivity of Ca2+ release either to caffeine or 4-chloro-m-cresol. No significant differences
were observed in stored Ca2+ release when control cells and cells expressing p.Arg2435Leu
heterozygously were exposed to caffeine or 4-chloro-m-cresol; however, cells carrying the
mutation at the homozygous state, released significantly less Ca2+ after pharmacological
activation (fig. 1C). Interestingly, the mutation at the heterozygous state diminished the peak
of Ca2+ release by greater than 2-fold, when a maximally activating KCl concentration (100
mM) was applied (fig. 1C). No significant differences in PN200-110 binding between control
and p.Arg2435Leu homozygous mutation carrying cells were found (the Bmax for control,
heterozygous and homozygous mutant cells was 60.9±12.1, 73.2±9.0 and 69.8±6.9 pmoles
PN200-110 bound/mg protein, respectively) indicating that the patient harbouring the RYR1
mutation does not have altered DHPR expression levels. Our results using myoD transduced
skin fibroblasts are in partial support with the data of Dirksen and Avila, who showed that in
dyspedic myotubes transduced with the RYR1 cDNA encoding the p.Arg2435Leu mutation,
the maximal voltage-activated Ca2+ release was reduced [26]. However, at variance with their
data, we found that the presence of the p.Arg2435Leu mutation does not affect resting [Ca2+]
(Figure 1 D).
To more directly analyse the functional consequences of the p.Arg2435Leu mutation, HEK293
cells were transfected with wild type or mutant RYR1 cDNAs. Crude membrane fractions were
prepared from the cells, and the sensitivity of recombinant channels to caffeine and Ca2+ was
determined. To simulate in vivo conditions, experiments were done in presence of 5 mM
Mg2+, 5mM AMPPCP (a nonhydrolyzable ATP analogue), and 5 mM reduced glutathione. As
shown in figure 2A, the p.Arg2435Leu substitution causes a small but significant increase in
[3H]ryanodine binding at low (μM) and high (mM) calcium concentrations. Caffeine sensitivity
was determined at 0.15 μM free Ca2+. In accordance with increased [3H]ryanodine binding at
low Ca2+ concentrations, mutant channels exhibited an increased level of [3H]ryanodine
binding in the presence of 1–5 mM caffeine compared to WT (Fig. 2B). Similar [3H]ryanodine
binding levels were obtained at 10 and 20 mM caffeine. We conclude that the p.Arg2435Leu
substitution increases the sensitivity of RyR1 to low and high concentrations of Ca2+ compared
to WT without a noticeable shift in sensitivity to caffeine.
In order to gain insight into the biophysical properties of the channels harbouring the
p.Arg2435Leu substitution, the single channel properties of recombinant wild type and mutant
RyR1s were compared. Figures 3A and C show that mutant channels exhibited some small but
significant increases in channel activity at low (0.1 μM) and high (10 mM) free Ca2+. Kinetic
analysis indicates a significant increase in the number of channel events and mean open and
closed (10 mM Ca2+ only) times of mutant channels compared to WT (Table 1). The
p.Arg2435Leu substitution did not significantly alter the K+ conductance and Ca2+ over K+
permeability ratio of mutant channels compared to WT (Fig. 3B).
From the results of the present and other investigations, it appears that the impact of the
substitution of Arg2435 is quite complex and may relate to several variables, including the
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genotype of the carrier (homozygous vs heterozygous) and the actual substituted residue. In
fact, several groups have reported the presence of a similar but not identical dominant
p.Arg2434His mutation in CCD/MH families [14–17]. The biochemical properties of amino
acid residues Leu, His and Arg are quite diverse: the former is a non-polar, non-charged residue,
the latter carries a positively charged polar side chain, while His is a polar residue whose charge
is strongly influenced by pH, being approximately 50% positively charged at physiological pH
[27]. Thus the substitution of His or Leu for Arg, most likely has a different effect on ryanodine
receptor channel function and we would like to emphasize that the results of the present
investigation can only be viewed in light of the p.Arg2435Leu substitution. In view of the
results of the present study, it is plausible that the p.Arg2435Leu residue contributes to
allosteric interactions that are important for transducing the E-C coupling signal to the pore
region of RyR1; an altered signal leads to channels with an increased Po particularly evident
at low (nanomolar) and high (millimolar) [Ca2+].
As to the presence of the heterozygous mutation in MH individuals, our results do not show
the typical increase in sensitivity to caffeine and 4-chloro-m-cresol observed in association
with p.Arg2435His expression in HEK293 cells [18] or an increased resting [Ca2+], typically
observed in many cells expressing MHS-linked mutations [22,28]. In this context, our results
are at variance with those of Dirksen and Avila [26] as they observed an increase in resting
[Ca2+], whereas we did not. This difference may be linked to differences in the experimental
models. We measured the activity of endogenously expressed RyR1s in myoD transduced skin
fibroblasts, whereas Dirksen and Avila over-expressed the mutant RYR1 cDNA in dyspedic
myotubes [26]. In a recent paper, we showed that myoD transduced fibroblasts harbouring the
compound S71Y+N2283H mutations (the latter being linked to the MHS phenotype) had a
small but significantly higher resting [Ca2+] compared to cells from controls, or from cells
bearing other RYR1 substitutions linked to recessive core myopathies [13]. Thus, cells from
the patients carrying the p.Arg2435His are apparently better equipped to handle the increased
Ca2+ leak occurring through the RyR1 mutant channels either because of a smaller leak and/
or more efficient re-uptake and extrusion mechanisms.
In conclusion, the present study shows that the homozygous p.Arg2435Leu mutation found in
a CCD patient is complex but compatible with a class 2 channel defect. MyoD transduced
fibroblasts from the homozygous patient and studies using the recombinant mutant construct,
indicate a “leaky” channel with increased channel activity. However, myoD transduced
fibroblasts from the heterozygous parents exhibited partial functional uncoupling of the RyR1
from the DHPR since they exhibited reduced depolarization-induced Ca2+ release (class 3
channel defect). Interestingly, the latter effect does not manifest itself in the heterozygous
parents because they are both clinically unaffected.
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Figure 1. Comparison of intracellular calcium homeostasis in myotubes from controls and
p.Arg2435Leu heterozygous and homozygous mutation-bearing individuals
Dose response curves of fura-2 loaded myotubes to to (A) caffeine and (B) 4-chloro-m-cresol.
Myotubes were individually stimulated by addition of the agonist in Krebs-Ringer buffer
containing no added Ca2+ and 100 μM La3+, thus the increase in [Ca2+]i represents only release
of calcium from intracellular stores. Curves show the caffeine, 4-chloro-m-cresol and caffeine
dose dependent changes in calcium, expressed as Δ in fluorescence ratio (peak ratio 340/380
nm-resting ratio 340/380 nm). Each point represents the mean (±S.E.) of the Δ fluorescence
of measurements performed on 8–36 different cells (open circles, straight line, controls; half
full box, dash-dot line, heterozygous; closed boxes, dotted line, homozygous). Dose response
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curves were generated using the Origin software. (C) Comparison of peak Ca2+ release after
addition of KCl, caffeine and 4-chloro-m-cresol and (D) resting [Ca2+] (as fluorescent ratio)
or. Values represent the mean± SEM of n number of different cells; *P<0.028, **P<0.015.
Open bars= control, light grey bars= heterozygous, dark grey bars= homozygous. For 100 mM
KCl n= 13, 21 and 8; for 10 mM caffeine n= 16,18 and 29; for 600 μM 4-cmc n= 23, 38 and
27; for resting [Ca2+] n= 149, 147 and 182 in control, heterozygous and homozygous mutation
bearing cells, respectively.
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Figure 2. Calcium and caffeine dependence of [3H]ryanodine binding to recombinant WT-RyR1
and RyR1-Arg2435Leu mutant
(A) Specific [3H]ryanodine binding to crude membrane fractions containing WT or mutant
RyR1 was carried out as described in Methods in 0.25 M KCl, 20 mM imidazole pH 7.0
containing, 5 mM Mg2+, 5 mM AMPPCP, 5 mM glutathione (reduced), 1.5 nM [3H]ryanodine
and the indicated free [Ca2+]. (B) Caffeine dependence was determined at 0.15 μM free
Ca2+. Data represent the mean± SD of 3 experiments.
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Single channel activities and conductances of WT and p.Arg2435Leu RyR1 ion channels.
(A) Traces represent single channel currents (openings shown as downward deflections from
the closed state, c) of WT RyR1 (left) and RyR1-Arg2435Leu (right) at −35 mV recorded in
symmetrical 250 mMKCl, 2 mMMgATPcis and indicated concentrations of free cis (cytosolic)
Ca2+. (B) Current voltage relationships of WT (solid symbols) and RyR1-Arg2435Leu (open
symbols) in symmetrical 250 mM KCl, 2 μM Ca2+ cis (circles) and following addition of 10
mM trans Ca2+ (triangles). No significant differences were observed between WT (closed
symbols) and R2435L (open symbols) RyR1. One of four similar experiments is shown. (C)
Ca2+ dependence of WT RyR1 and RyR1-Arg2435Leu single channel open probabilities (Po)
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in symmetrical 250 mM KCl, 2 mM MgATP cis and indicated concentrations of free cis
(cytosolic) Ca2+. Data are the mean ± S.E. of 6–19 experiments.
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Table 1
Single channel parameters of WT-RyR1 and RyR1-R2435L
WT-RyR1 RyR1-R2435L
0.1 μM free Ca2+
Po 0.003±0.002(8) 0.074±0.037(5)*
Number of events/min 183±74 786±324*
Mean open time (ms) 0.77±0.15 4.01±1.32*
Mean closed time (ms) 1607±697 184±84
10 mM free Ca2+
Po 0.006±0.001(8) 0.109±0.047(8)*
Number of events/min 1374±298 17394±5243 *
Mean open time (ms) 0.24±0.01 0.31±0.03*
Mean closed time (ms) 68.8±18.7 7.01±2.41*
Single channel activities were determined as in Fig. 2 with 0.1 μM and 10 mM free Ca2+ in the cis chamber. Data are the mean ± S.E. of number of
experiments in parenthesis.
*
P<0.05 compared with WT-RyR1.
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